EVALUATION OF AN INTERMITTENT SCHEDULE OF DIBROMODULCITOL IN BREAST-CANCER

  • 1 January 1976
    • journal article
    • research article
    • Vol. 60  (11) , 1593-1597
Abstract
Dibromodulcitol was administered orally on days 1-10 every 3-4 wk to 29 patients with metastatic breast carcinoma refractory to previous combination chemotherapy. Initial doses between 70 and 280 mg/m2 per day were utilized. The dose was escalated as tolerated in subsequent cycles in individual patients. Hematosuppression was dose limiting. At doses of < 200 mg/m2 per day leukopenia (< 1000 cells/mm3) and thrombocytopenia (< 25,000 platelets/mm3) occurred in 1 of 28 cycles and 2 of 27 cycles, respectively. At doses of .gtoreq. 200 mg/m2 per day leukopenia and thrombocytopenia occurred in 4 of 18 cycles and 5 of 18 cycles, respectively. Recovery of leukocytes (> 4000 cells/mm3) and platelets (> 100,000 platelets/mm3) by day 29 after the start of therapy was also delayed at higher doses. Responses were observed in 3 of 29 evaluable patients and subjective improvement of osseous disease in 1 additional patient. A dose of 180 mg/m2 per day .times. 10 every 28 days is recommended in previously treated patients to avoid severe hematologic side effects.

This publication has 1 reference indexed in Scilit: